Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yixin Powder for Stable Angina Pectoris in Coronary Heart Disease
NCT07378228Completed
- Sponsor
- Xikun Li
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of Yixin Powder in stable angina pectoris (2 arms), sponsored by Xikun Li. Primary endpoints: Response Rate based on Traditional Chinese Medicine (TCM) Syndrome Score Improvement at 4 weeks and Response Rate based on Electrocardiogram (ECG) Improvement at 4 weeks. Started Jul 2023; status: completed.
02
Drugs
Yixin Powder
03
Conditions
stable angina pectoris
Beyond the preview
Go deeper on NCT07378228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07378228.